Contrast injector technology firm Medrad has signed an agreement to provide technology to Massachusetts General Hospital (MGH) in Boston for use in the institution's functional pulmonary PET imaging research.
An MGH team is developing a second-generation custom device to prepare and inject molecular agents using Medrad's controlled fluid delivery technology and programming interface capabilities, according to Medrad of Warrendale, PA.
The MGH device will process and inject nitrogen-13 gas dissolved in saline for use in both preclinical and clinical PET studies. The technique enables acquisition of spatially coregistered functional images of lung perfusion and ventilation in a single procedure, according to Medrad.
Related Reading
Medrad, Pinestar team up, May 19, 2010
Medrad opens US probe service center, March 24, 2010
Medrad to launch contrast IT platform, November 23, 2009
Merge and Medrad extend European reach, October 30, 2009
Medrad inks Florida research deal, August 25, 2009
Copyright © 2010 AuntMinnie.com
